5d 1m 3m 1y 5y 10y
There are no Transcripts on PBTH.
PBTH vs. ETF Alternatives
Thursday, Aug 292013, 4:09 PM
Thursday, Aug 292013, 4:09 PM| 9 Comments
- Opko Health (OPK -1%) says it's completed its acquisition of Prolor Biotech (PBTH).
- Under the terms of the deal, each PBTH stockholder will receive 0.9951 shares of OPK.
- The acquisition provides OPK with four significant products in Phase III clinical development, as well as a pipeline of important therapeutic and unique diagnostic products in various stages of development.
Wednesday, Jul 32013, 8:53 AMProlor Biotech (PBTH) is due to present preclinical data tomorrow providing further evidence that its Factor VIIa-CTP hemophilia therapy can be administered with an injection as well as intravenously. Providing the clotting agent via an injection would facilitate its prophylactic use by patients as a way to prevent bleeding rather than just for when a bleeding episode occurs. Prolor Biotech hopes to start two clinical trials for the treatment next year. (PR) |Wednesday, Jul 32013, 8:53 AM| Comment!
Tuesday, Jun 42013, 11:54 AMProlor Biotech (PBTH -2%) says it's initiated Phase III clinical trials of hGH-CTP, a human growth hormone that provides deficient adults and children with hGH therapy that may require only once-weekly or bi-monthly injections, rather than the daily injections required by current hGH therapy. |Tuesday, Jun 42013, 11:54 AM| Comment!
Wednesday, Apr 242013, 9:11 AM
Wednesday, Apr 242013, 9:08 AMProlor Biotech (PBTH), will be acquired by OPKO Health (OPK) in an all-stock deal worth $480M. PBTH shareholders will get 0.9551 shares of OPK for every share of PBTH they own, equating to $7 per share as of Tuesday's closing prices. PBTH +10.65% premarket. (Previously: strategic alternative evaluation boosts Prolor) |Wednesday, Apr 242013, 9:08 AM| 3 Comments
Thursday, Apr 112013, 12:49 PMMidday top 10 gainers: ACAD +55%. RNIN +26%. RAD +18%. ZUMZ +15%. MEA +13%. BIOL +12%. MGT +12%. PBTH +12%. MPAC +11%. TVL +11%.
Midday top 10 losers: LEDS -17%. FTNT -14%. ROYL -14%. NTIC -16%. HXM -11%. CREG -11%. PRMW -10%. GNVC -10%. SGYP -10%. OCZ -10%. |Thursday, Apr 112013, 12:49 PM| Comment!
Thursday, Apr 112013, 11:02 AMProlor Biotech (PBTH +8.2%) hires Jefferies Group to evaluate strategic alternatives. An unnamed source says the company has drawn interest from big pharma over the past 12 months, but notes PBTH has not decided to sell itself. SA contributor Daniel Lauchheimer's article suggesting the stock has "unlimited upside" looks prescient. (See also: PBTH gets orphan drug designation) |Thursday, Apr 112013, 11:02 AM| Comment!
Wednesday, Feb 132013, 11:14 AMProlor Biotech (PBTH +4.2%) gets a boost from an orphan drug designation for hGH-CTP, a long-acting treatment for growth hormone deficiency from the European Commission and the European Medicines Agency. The approval marks the first time a growth hormone has received any such a designation in Europe, and once launced, the drug will receive 10 years of marketing exclusivity in Europe. |Wednesday, Feb 132013, 11:14 AM| Comment!
Wednesday, Oct 32012, 9:27 AMProlor Biotech (PBTH) +8.3% premarket after receiving a notice of allowance from the U.S. patent office for a new patent application covering its long-acting CTP-enhanced human growth hormone. The patent gives PBTH additional intellectual property protection covering methods for the induction of growth in growth hormone deficient patients. |Wednesday, Oct 32012, 9:27 AM| Comment!
Friday, May 112012, 9:15 AM
Tuesday, Apr 172012, 9:56 AMProlor Biotech (PBTH +4.9%) reports positive pre-clinical results from an animal study for its obesity and Type II diabetes drug candidate MOD-6030. When administered once a week over 30 days, PBTH says the treatment produced an average weight loss of 28% and a 19% reduction in blood glucose levels. |Tuesday, Apr 172012, 9:56 AM| Comment!
Wednesday, Jan 182012, 8:19 AMPROLOR Biotech (PBTH) announces that it achieved positive top-line results from a study of its human growth hormone tested in a Phase II clinical study. The results indicate the firm's drug may be able to achieve the same results as currently marketed treatments with fewer injections required. Shares +3.8% premarket. |Wednesday, Jan 182012, 8:19 AM| Comment!
Tuesday, Jan 172012, 10:41 AMProlor Biotech (PBTH +11.1%) follows up last week's strong gains with a double-digit move up. M.E. Garza attributes the buying to M&A chatter emerging out of a major healthcare conference last week in San Francisco on the strength of the firm's promising drug pipeline. |Tuesday, Jan 172012, 10:41 AM| Comment!
Wednesday, Jul 132011, 10:57 AMPROLOR Biotech (PBTH) pops today, +11.3% to $5.61, after yesterday's initiation of coverage by Morgan Joseph at Buy with a target of $16. Also this week, Summer Street initiated coverage with a target of $8. The company develops therapeutic proteins and has full Phase II trial results ahead. |Wednesday, Jul 132011, 10:57 AM| Comment!
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.